CHOLECALCIFEROL (VITAMIN D3)
VITAMIN D · HYPOPARATHYROIDISM ·+6
LEADER
Drug class
Vitamin D
The vitamin D therapeutic drug class comprises fat-soluble secosteroid compounds and analogs, most notably ergocalciferol and cholecalciferol, that function as essential hormonal precursors in mineral homeostasis. Read more about Vitamin D
307 drugs in this class 101 manufacturers
Drugs in Vitamin D
PARICALCITOL
VITAMIN D · HYPERPARATHYROIDISM SECONDARY TO CHRONIC RENAL FAILURE
AUROBINDO PHARM
PARICALCITOL
VITAMIN D · HYPERPARATHYROIDISM SECONDARY TO CHRONIC RENAL FAILURE
BIONPHARMA INC.
PARICALCITOL
VITAMIN D · HYPERPARATHYROIDISM SECONDARY TO CHRONIC RENAL FAILURE
TIME-CAP LABS
MULTI-VITAMIN W-FLUORIDE-IRON (pediatric multivitamin no.45/sodium fluoride/ferrous sulfate)
FLUORIDES · VITAMIN DEFICIENCY ·+1
METHOD PHARMACE
MULTIVITAMIN-IRON-FLUORIDE (pediatric multivitamin no.45/sodium fluoride/ferrous sulfate)
FLUORIDES · VITAMIN DEFICIENCY ·+1
H2 PHARMA LLC
MULTIVITAMIN WITH FLUORIDE (pediatric multivitamin no.16/sodium fluoride)
FLUORIDES · VITAMIN DEFICIENCY ·+1
H2 PHARMA LLC
VITAMINS A,C,D AND FLUORIDE (pediatric multivit with A,C,D3 no.21/sodium fluoride)
FLUORIDES · VITAMIN DEFICIENCY ·+1
H2 PHARMA LLC
INTERNATIONAL V
Filter & compare in the drug finder →
Opens the drug finder with Vitamin D preselected. Add indication or manufacturer filters there.
The vitamin D therapeutic drug class comprises fat-soluble secosteroid compounds and analogs, most notably ergocalciferol and cholecalciferol, that function as essential hormonal precursors in mineral homeostasis.
Agents in this class undergo sequential hepatic and renal hydroxylation into biologically active forms that bind intracellular vitamin D receptors, enhancing intestinal absorption and renal reabsorption of calcium and phosphate while regulating bone remodeling.
Clinically, these agents are primarily indicated for the prevention and treatment of nutritional rickets, osteomalacia, osteoporosis, hypocalcemia associated with hypoparathyroidism, and metabolic bone disease secondary to chronic kidney disease.
-
fda.gov
The vitamin D therapeutic drug class comprises fat-soluble secosteroid compounds and analogs, most notably ergocalciferol and cholecalciferol, that function as essential hormonal precursors in mineral homeostasis
-
fda.gov
The vitamin D therapeutic drug class comprises fat-soluble secosteroid compounds and analogs, most notably ergocalciferol and cholecalciferol, that function as essential hormonal precursors in mineral homeostasis Agents in this class undergo sequential hepatic and renal hydroxylation into biologically active forms that bind intracellular vitamin D receptors, enhancing intestinal absorption and renal reabsorption of calcium and phosphate while regulating bone remodeling Clinically, these agents a...
-
cancer.gov
The vitamin D therapeutic drug class comprises fat-soluble secosteroid compounds and analogs, most notably ergocalciferol and cholecalciferol, that function as essential hormonal precursors in mineral homeostasis
-
nih.gov
Agents in this class undergo sequential hepatic and renal hydroxylation into biologically active forms that bind intracellular vitamin D receptors, enhancing intestinal absorption and renal reabsorption of calcium and phosphate while regulating bone remodeling Clinically, these agents are primarily indicated for the prevention and treatment of nutritional rickets, osteomalacia, osteoporosis, hypocalcemia associated with hypoparathyroidism, and metabolic bone disease secondary to chronic kidney d...
-
nih.gov
Agents in this class undergo sequential hepatic and renal hydroxylation into biologically active forms that bind intracellular vitamin D receptors, enhancing intestinal absorption and renal reabsorption of calcium and phosphate while regulating bone remodeling
-
fda.gov
Clinically, these agents are primarily indicated for the prevention and treatment of nutritional rickets, osteomalacia, osteoporosis, hypocalcemia associated with hypoparathyroidism, and metabolic bone disease secondary to chronic kidney disease
-
fda.gov
Clinically, these agents are primarily indicated for the prevention and treatment of nutritional rickets, osteomalacia, osteoporosis, hypocalcemia associated with hypoparathyroidism, and metabolic bone disease secondary to chronic kidney disease
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.